Morgan Stanley initiated coverage of Option Care Health (OPCH) with an Overweight rating and $35 price target The company is well positioned amid rising prevalence of chronic disease and focus on lower-cost care centers, the analyst tells investors in a research note. The firm says Option Care is a leader in the home and alternative-site infusion market, offering a critical solution to the healthcare system.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health: Positioned for Growth in the Expanding Infusion Market
- These 3 “Strong Buy” Value Stocks Have over 20% Upside, According to Analysts – 10/14/2025
- Option Care Health: Strong Market Position and Financials Balanced by Lack of Near-Term Catalysts
- Option Care Health initiated with a Hold at TD Cowen
- Option Care Health Amends Credit Agreement for Refinancing